InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,000.01
(
0.27%
)
US TECH 100
20,520.80
(
0.02%
)
Dow Jones
44,100.90
(
0.43%
)
Brent Oil
72.33
(
0.99%
)
Bitcoin
92,018.22
(
4.69%
)
Post# of 8313
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

walkman

Send PM Follow Ignore
Followers 0
Posts 18
Boards Moderated 0
Alias Born 10/24/2007

walkman

Re: Long-vestor post# 3506

Tuesday, 02/19/2008 3:34:02 PM

Tuesday, February 19, 2008 3:34:02 PM

Post# of 8313
Other interesting notes/questions on call....

Although they did not give margins on product by product, I thought it was interesting that their margins on 2 drugs were 35% (I think they were Clarythromycin and Itopride - correct me if I am wrong please)

When asked if they were looking at other markets Elsa indicated that China is where they will get the best bang for their buck - they mentioned that they were present in 30 out of 32 regions/provinces

Sales on recently released OTC Baobaole in first month (December) were 15% more than expected.

Also regarding 2 drugs in final approval stage did Elsa intimate that they were only waiting for approval "stuff" like on product packaging? I think she also said that they expected to launch by end of fiscal 08?


Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up